Daiichi Sankyo announced that it has received approval from Japan’s Ministry of Health, Labour and Welfare for Daichirona® for IV injection as an Omicron XBB.1.5-adapted monovalent mRNA vaccine against COVID-19. Daichirona® is the first Japanese-made mRNA vaccine, and will be distributed in the coming days in Japan.
On 19 October 2023, Daiichi and Merck announced a global development and commercialisation collaboration involving Daiichi’s three deruxtecan antibody-drug conjugate candidates: patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan.